1544 related articles for article (PubMed ID: 18196538)
1. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
2. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
3. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
6. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
7. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.
Zou JX; Zhong Z; Shi XB; Tepper CG; deVere White RW; Kung HJ; Chen H
Prostate; 2006 Oct; 66(14):1474-86. PubMed ID: 16921507
[TBL] [Abstract][Full Text] [Related]
8. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
11. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
12. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
13. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
15. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
17. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
20. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]